RAN and myotonic dystrophy type 1: It remains to be determined if the correction of the additional molecular players in DM1 and in DM2, such as microRNAs [27], and the reduction in the accumulation of abnormal peptides synthesized due to RAN translation [25,26] would be beneficial in clinical trials for patients with these diseases.